JUDY WOODRUFF: The prices of health treatment are
a wallet issue for most Americans, and climbing medicine rates, a key part of that. Individuals in the U.S. spend much more on prescription
medications than in any type of various other nation, regarding $1,200 a year each. Insurance firms and also the government pay the biggest
share. But it'' s setting you back customers more money in costs
as well as expense. Rage has actually been developing over affordability
as well as specialized medicines that set you back tens of thousands of dollars. That was the backdrop for a much-anticipated
Us senate hearing today involving the medicine manufacturers. John Yang has that report. JOHN YANG: It has been decades considering that this
numerous leaders of the leading medicine producers have faced lawmakers under oath.Senators in both parties lashed out at their earnings margins as well as pressed them to discuss why medicine rates keep increasing. SEN. RON WYDEN( D), Oregon: All of you that are right here today are right here due to the fact that the means you have been
operating is inappropriate. JOHN YANG: Money Board Chairman Chuck Grassley set the tone, tearing into the executives of 7 pharmaceutical titans for shirking obligation. SEN. CHARLES GRASSLEY (R), Iowa: Another yes-or-no inquiry:
When you ' re firm costs its medicines, do you take into consideration the
fact that a key player is the federal government? Allow ' s begin with AbbVie. RICHARD GONZALEZ, CEO, AbbVie Laboratories: We review all the networks when we make determinations on rate and price. SEN. CHARLES GRASSLEY: So, that certainly would consist of the federal government? AstraZeneca. PASCAL SORIOT, CHIEF EXECUTIVE OFFICER, AstraZeneca: Yes, we do. SEN. CHARLES GRASSLEY: OK, Bristol-Myers. MAN: Yes, Senator. SEN. CHARLES GRASSLEY: Johnson & Johnson. WOMAN: Yes.SEN. CHARLES GRASSLEY: Merck. KENNETH C. FRAZIER, CEO, Merck: Yes. SEN. & CHARLES GRASSLEY: Pfizer. MAN: Absolutely. SEN. CHARLES GRASSLEY: As Well As Sanofi. GUY: Yes. JOHN YANG: The execs all stated they were happy to do more to make certain individuals can manage the medications they need,
yet provided couple of information. They claimed intermediaries were to blame, which establishing new medications calls for billions of bucks in study. PASCAL SORIOT: Our firm is dedicated to scientific research as well as technology. And also in 2018, we invested virtually$ 6 billion in r & d. KENNETH C. FRAZIER: We ' re proud to have actually deployed 70,000 doses of our experimental Ebola injection in the Congo. JENNIFER TAUBERT, Executive Vice President, Janssen: We focus on discovering and also establishing transformational medications for several of the world ' s most difficult illness, consisting of several myeloma, prostate cancer, HIV, schizophrenia, as well as Crohn ' s condition, amongst others. Janssen spent$ 8.4 billion in research study and also development in 2014 in the search
for medical innovations. JOHN YANG: Democrat Maria Cantwell of Washington state pressed the execs to recognize that the federal government might aid bring costs down.SEN. MARIA CANTWELL (D), Washington:
I ' m asking a really standard inquiry, like the VA ' s capacity to discuss on medication costs.
Do you assume that states having that exact same capability drives down
rate? KENNETH C. FRAZIER: I would claim that the VA. would certainly obtain a reduced price and the states would certainly obtain a reduced price if you ' re ready to go. right into an environment where that might be
imposed by the states. SEN. MARIA CANTWELL: Or the federal government? JOHN YANG: The hearing comes as President. Trump targets drug expenses. He ' s suggested finishing Medicare and also Medicaid. discounts to intermediaries and also reducing the rate Medicare pays for some drugs.
DONALD TRUMP, President of the USA:. At long last the medicine companies in international countries will be held answerable for how. they rigged the system versus American consumers. JOHN YANG: Today, senators threatened legislative. activity. Several zeroed in on Richard Gonzalez, CHIEF EXECUTIVE OFFICER. of AbbVie, the maker of Humira. It ' s the successful drug in the globe used. for rheumatoid joint inflammation as well as other illness,
annual sales nearly$ 20 billion. Over the last 6 years, the drug ' s rate. has doubled to$ 38,000 a year.More than 100 AbbVie patents as well as manage. various other medicine makers mean that lower-price rivals will not strike the united state market prior to 2023'.
SEN. JOHN CORNYN (R), Texas: The amount of patents? I ' m sorry. RICHARD GONZALEZ: One hundred
as well as thirty-six. SEN. JOHN CORNYN: One hundred and thirty-six licenses. on one medicine? RICHARD GONZALEZ: However, well, remember, Humira. resembles 9 various drugs or 10 different drugs. SEN. JOHN CORNYN: I thought you said to Legislator. Stabenow it coincided particle.
RICHARD GONZALEZ: It is the exact same particle,.
yet it deals with different condition, as well as if you look at that patent portfolio … (CROSSTALK) SEN. JOHN CORNYN: So,
you utilize the very same molecule. to treat different conditions, you can obtain a license on that particular treatment? RICHARD GONZALEZ: Definitely. SEN.JOHN CORNYN: Mr. Chairman, I recognize this subject. is the topic of– or within the jurisdiction of the Finance Board, yet those of us. like you and also me that are also on the Judiciary Committee that has territory over the patent. system, I think this is an area that we need to search in via our Judiciary Committee. authority.
JOHN YANG: Senator Ron Wyden of Oregon, the. panel ' s top Democrat, asked Gonzalez if his compensation, which was$ 22 million in 2017,. is connected to Humira sales. SEN. RON WYDEN: Would certainly you make a smaller sized benefit. if you went down the cost of Humira? RICHARD GONZALEZ: Humira was one element of. a set of economic factors that were evaluated as part of my compensation. It ' s clearly an extremely considerable item. for us, so it ' s clear that it would belong to that analysis. SEN. RON WYDEN: I would like that in creating within. 10 days. JOHN YANG: Some CEOs, like Merck ' s Ken Frazier,. stated they wanted to do things like eliminating discounts that help protect their market share,. yet, overall, business defended their practices.KENNETH C. FRAZIER: Nobody company can unilaterally. reduced retail price without facing economic and also running negative aspects. JOHN YANG: By the hearing ' s end, Wyden and also. various other legislators claimed they were much from pleased. SEN. RON WYDEN: I have actually heard a lot of delighted talk. this early morning. JOHN YANG: Today ' s listening to
featured a lot more bipartisan. criticism than in the past, yet it is far from clear what activity Congress will take. as medicine prices remain to rise. For the “PBS NewsHour,” I ' m John Yang.
